These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 21210134)

  • 21. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
    Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome?
    La Marca A; Pati M; Giulini S; Levratti P; Caretto S; Volpe A
    Gynecol Endocrinol; 2005 Nov; 21(5):292-4. PubMed ID: 16373249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease.
    Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF
    Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial.
    Palomba S; Falbo A; Di Cello A; Cappiello F; Tolino A; Zullo F
    Fertil Steril; 2011 Nov; 96(5):1128-33. PubMed ID: 21917254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled ovarian stimulation with exclusive FSH followed by stimulation with hCG alone, FSH alone or hMG.
    Gomes MK; Vieira CS; Moura MD; Manetta LA; Leite SP; Reis RM; Ferriani RA
    Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):99-106. PubMed ID: 16835006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcome.
    Selman H; Pacchiarotti A; El-Danasouri I
    Fertil Steril; 2010 Oct; 94(5):1782-6. PubMed ID: 19939369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triggering with 1,500 IU of human chorionic gonadotropin plus follicle-stimulating hormone compared to a standard human chorionic gonadotropin trigger dose for oocyte competence in in vitro fertilization cycles: a randomized, double-blinded, controlled noninferiority trial.
    Anaya Y; Cakmak H; Mata DA; Letourneau J; Zhang L; Lenhart N; Juarez-Hernandez F; Jalalian L; Cedars MI; Rosen M
    Fertil Steril; 2022 Aug; 118(2):266-278. PubMed ID: 35705380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
    Mitwally MF; Casper RF
    J Soc Gynecol Investig; 2004 Sep; 11(6):406-15. PubMed ID: 15350255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose FSH stimulation in polycystic ovary syndrome: comparison of 3 FSH-preparations.
    Strowitzki T; Seehaus D; Korell M; Hepp H
    Exp Clin Endocrinol Diabetes; 1998; 106(5):435-9. PubMed ID: 9831312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical application of in vitro maturation of human immature oocytes for infertile women with polycystic ovary syndrome].
    Xu YP; Xiang HF; Zou WW; Li ZL; Zhang ZG; Zhou P; Cao YX
    Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):14-8. PubMed ID: 22455687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial.
    Madani T; Mohammadi Yeganeh L; Khodabakhshi S; Akhoond MR; Hasani F
    J Assist Reprod Genet; 2012 Nov; 29(11):1213-20. PubMed ID: 22956348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.
    Kolibianakis EM; Albano C; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Fertil Steril; 2004 Jul; 82(1):102-7. PubMed ID: 15236997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome.
    Chian RC; Buckett WM; Tulandi T; Tan SL
    Hum Reprod; 2000 Jan; 15(1):165-70. PubMed ID: 10611207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.